GLP-1 New Drug R&D Platform
Expanding the hypoglemic strategy
Type 2 diabetes is a progressive disease. The disease course is primarily characterized by a decline in β-cell function and worsening of insulin resistance. Therefore, various antidiabetic agents are under research and development. The hypoglycemic strategy has also shifted from "sugar control" to both "sugar control" and "heart protection". GLP-1R agonists can improve left ventricular ejection fraction, myocardial contractility, coronary blood flow, cardiac output, and endothelial function while reducing infarction size and overall risks for a cardiovascular event. Other functions of GLP-1 include increased glucose uptake in the muscles, decreased glucose production in the liver, neuroprotection, and increased satiety due to direct actions on the hypothalamus. At present, the therapeutic application and potential value of GLP-1RAs in diabetes has become a research hotspot.
In the formulation of GLP-1 integrated research plan, Medicilon has in-depth communication with customers. The backbone of scientific research has combined the characteristics of each case with years of practical experience and technical accumulation, and carefully submitted high-quality experimental plans and results to customers. Medicilon provides GLP-1 drug discovery, CMC research (API + formulation), pharmacodynamics research, PK study, GLP-1 safety evaluation and other services. As of the end of June 2023, Medicilon has successfully assisted in the clinical approval of 8 GLP-1 drugs (3 approved by FDA and NMPA, 1 approved by FDA, NMPA, and TGA) and has multiple GLP-1 projects under development.